Scan to Download ios&Android APP

Trade IMARA Inc. - IMRA CFD

-
0%

IMARA Inc. live chart

Still looking for a broker you can trust?
Capital.com Group
400,000+

Traders

90,000+

Active clients monthly

$65,000,000+

Monthly investing volume

$29,000,000+

Withdrawn each month

  • Summary
  • Historical Data
Trading Conditions
Long position overnight fee
-0.0225%
Short position overnight fee
-0.0219%
Overnight fee time
21:00 (UTC)
Min traded quantity
1
Currency
USD
Margin
20%
Stock exchange
United States of America
Commission on trade
0%
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low

Content 2
Content 2

Key Stats

Prev. Close* N/A
Open* N/A
Day's Range* N/A
1-Year Change* N/A
Volume N/A
Average Vol. (3m) 6.67721
52 wk Range N/A
Market Cap 27.5895
P/E Ratio N/A
Shares Outstanding 26.28M
Revenue N/A
EPS -2.39141
Dividend (Yield %) N/A
Beta N/A
Next Earnings Date Aug 4, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

IMARA Inc. Company profile

About Imara Inc

Imara, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing novel therapeutics to treat rare inherited genetic disorders of hemoglobin. The Company’s product pipeline includes IMR-687 (tovinontrine). IMR-687 is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD and beta-thalassemi. IMR-687 is a selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9), that has a multimodal mechanism of action that acts primarily on red blood cells (RBCs) and has the potential to act on white blood cells (WBCs), adhesion mediators and other cell types. PDE9 decreases cyclic guanosine monophosphate (cGMP), an active signaling molecule. The Company is conducting Phase II b clinical trials of IMR-68.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Imara Inc revenues was not reported. Net loss applicable to common stockholders increased 4% to $51.4M. Higher net loss reflects G&A increase of 20% to $10.6M (expense), Stock-based Compensation in SGA increase from $741K to $2.4M (expense), Interest income decrease of 52% to $233K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$3.53 to -$2.37.

Industry: Biotechnology & Medical Research (NEC)

116 Huntington Avenue
6Th Floor
BOSTON
MASSACHUSETTS 02116
US

People Also Watch

Bitcoin to US Dollar

20,861.95 Price
-0.050% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 21:00 (UTC)
Spread 66.00

Still looking for a broker you can trust?

Join the 400.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading